Management of choroidal neovascularization in uveitis

International Ophthalmology Clinics

Volumn 45, Issue 2, 2005, Pages 157-177

  O'Toole, Louise ^a   Tufail, Adnan ^a   Pavesio, Carlos ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANECORTAVE; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; FLUOCINOLONE ACETONIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; TRIAMCINOLONE; XENON;

BEAM THERAPY; CATARACT; CHOROIDITIS; CLINICAL TRIAL; DESENSITIZATION; DISEASE CLASSIFICATION; EYE SURGERY; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; LOW LEVEL LASER THERAPY; MULTIFOCAL CHOROIDITIS; OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PUNCTATE INNER CHOROIDITIS; REVIEW; SARCOIDOSIS; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; UVEITIS;

CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; HUMANS; UVEITIS, POSTERIOR;

EID: 17644376906     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000155902.49562.4a     Document Type: Review

References (80)

1. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol. 1994;118:285-298.
2. Woods AC, Wahlen HE. The probable role of benign histoplasmosis in the etiology of granulomatous uveitis. Am J Ophthalmol. 1960;49:205.
3. Olk RJ, Burgess DB, McCormick PA. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology. 1984;91:1592-1602.
4. Schlaegel TF, Weber JC, Helveston E, et al. Presumed histoplasmic choroiditis. Am J Ophthalmol. 1967;63:919-925.
5. Wheat J. Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore). 1997;76:339-354.
6. Dabil H, Kaplan HJ, Duffy BF, et al. Association of the HLA-DR15/HLA-DQ6 haplotype with development of choroidal neovascular lesions in presumed ocular histoplasmosis syndrome. Hum Immunol. 2003;64:960-964.
7. Meredith TA, Green WR, Key SN, et al. Ocular histoplasmosis: clinicopathologic correlation of 3 cases. Surv Ophthalmol. 1977;22:189-205.
8. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1991;111:1-7.
9. Reddy VM, Zamora RL, Kaplan HJ. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1995;120:291-301.
10. Saxe SJ, Grossniklaus HE, Lopez PF, et al. Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome. Arch Ophthalmol. 1993;111:88-95.
11. Lewis ML, Van Newkirk, Gass D. Follow up study of presumed ocular histoplasmosis syndrome. Ophthalmology. 1980;87:390-398.
12. Gass JD, Wilkinson CP. Follow-up study of presumed ocular histoplasmosis. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:672-694.
13. Elliott JH, Jackson DJ. Presumed histoplasmic maculopathy: clinical course and prognosis in non-photocoagulated eyes. Int Ophthalmol Clin. 1975;15:29-39.
14. Sawelson H, Goldberg RE, Annesley WH, et al. Presumed ocular histoplasmosis syndrome. The fellow eye. Arch Ophthalmol. 1876;94:221-224.
15. Macular Photocoagulation Study Group. Five year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Arch Ophthalmol. 1996;114:677.
16. Halperin LS, Akduman L, Olk RJ. Ocular histoplasmosis syndrome. In: Ryan SJ, Ogden TE, Hinton D, et al, eds. Retina. 3rd ed. St. Louis, MO: C. V. Mosby Company; 2001.
17. Gitter KA, Cohen G. Photocoagulation of active and inactive lesions of presumed ocular histoplasmosis. Am J Ophthalmol. 1975;79:428-436.
18. Suttorp-Schulten MSA, Bollemeijer JG, Bos PJM, et al. Presumed ocular histoplasmosis in the Netherlands: an area without histoplasmosis. Br J Ophthalmol. 1997;81:7-11.
19. Ciulla TA, Piper HC, Xiao M, et al. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. Curr Opin Ophthalmol. 2001;12:442-449.
20. Kleiner RC, Ratner CM, Enger C, et al. Subfoveal neovascularization in the ocular histoplasmosis syndrome. A natural history study. Retina. 1988;8:225-229.
21. Cummings HL, Rehmar AJ, Wood WJ, et al. Long-term results of laser treatment in the ocular histoplasmosis syndrome. Arch Ophthalmol. 1995;113:465-468.
22. Campochiaro PA, Morgan KM, Conway BP, et al. Spontaneous involution of subfoveal neovascularization. Am J Ophthalmol. 1990;109:668-675.
23. Fine SL, Wood WJ, Isernhagen RD, et al. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: results of a pilot randomized clinical trial. Arch Ophthalmol. 1993;111:19-20.
24. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103:2099-2104.
25. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378.
26. Martidis A, Miller DG, Ciulla TA, et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol. Ther. 1999;15:425-428.
27. Rechtman E, Allen VD, Danis RP, et al. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol. 2003;136:739-741.
28. Ciulla TA, Walker JD, Fong DS, et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15:211-220.
29. Dees C, Arnold JJ, Forrester JV, et al. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998;116:1456-1461.
30. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol. 1999;117:1329-1345.
31. Roberts WG, Hasan T. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res. 1992;52:924-930.
32. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of amurine tumor. Cancer Res. 1976;36:2326-2329.
33. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
34. Moan J, Peng Q, Evensen JF, et al. Photosensitizing efficiencies, tumor and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol. 1987;46:713-721.
35. Rosenthal I. Phthalocyanines as photodynamic photosensitizers. Photochem Photobiol. 1991;53:859-870.
36. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol. 2003;135:343-350.
37. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol. 2000;118:327-336.
38. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology. 2002;109:1499-1505.
39. Busquets MA, Shah GK, Wickens J, et al. Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina. 2003;23:299-306.
40. Wachtlin J, Heimann H, Behme T, et al. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol. 2003;241:899-906.
41. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1991;111:1-7.
42. Thomas MA, Grand MG, Williams DF, et al. Surgical management of subfoveal choroidal neovascularization. Ophthalmology. 1992;99:952-968; discussion 975-976.
43. Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101:1384-1396.
44. Berger AS, Kaplan HJ. Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results. Ophthalmology. 1992;99:969.
45. Berger AS, Conway MD, Del Priore LV, et al. Submacular surgery for subfoveal choroidal neovascular membranes in presumed ocular histoplasmosis. Arch Ophthalmol. 1997;115:991.
46. Holekamp NM, Thomas MA, Dickinson JD, et al. Surgical removal of subfoveal choroidal neovascularization in presumed ocular histoplasmosis: stability of early visual results. Ophthalmology. 1997;104:22-26.
47. Pavan PR, Margo CE. Submacular neovascular membrane and focal granulomatous inflammation. Ophthalmology. 1996;103:586-589.
48. Klein ML, Fine SL, Patz A. Follow up study in eyes with choroidal neovascularization caused by presumed ocular histoplasmosis. Am J Ophthalmol. 1977;83:830-835.
49. Fujii GY, Humayun MS, Pieramici DJ, et al. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol. 2001;131:90-100.
50. Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1983;101:1347-1357.
51. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:503-512.
52. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109-1114.
53. Cummings HL, Rehmar AJ, Wood WJ, et al. Long-term results of laser treatment in the ocular histoplasmosis syndrome. Arch Ophthalmol. 1995;113:465-468.
54. Macular Photocoagulation Study Group. Laser photocoagulation for neovascular lesions nasal to the fovea. Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes. Arch Ophthalmol. 1995;113:56.
55. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1987;105:1499-1507.
56. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Arch Ophthalmol. 1989;107:344-352.
57. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five year results from randomized clinical trials. Arch Ophthalmol. 1994;112:500.
58. Macular Photocoagulation Study Group. The influence of treatment extent on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularization. Arch Ophthalmol. 1995;113:190.
59. Atebara NH, Thomas MA, Holekamp NM, et al. Surgical removal of extensive peripapillary choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Ophthalmology. 1998;105:1598-1605.
60. Makley TA, Long JW, Suie T. Therapy of chorioretinitis presumed to be caused by histoplasmosis. Int Ophthalmol Clin. 1975;15:181.
61. Liem SE, Armbruster FC. Proton-beam irradiation of subfoveal choroidal neovascular membranes in presumed ocular histoplasmosis syndrome: a case report. J Am Optom Assoc. 1998;69:493-499.
62. Berger AS, Conway M, Del Priore LV, et al. Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol. 1997;115:991-996.
63. Deleted in press.
64. Brown J Jr, Folk JC, Reddy CV, et al. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103:1100-1105.
65. Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98:572-584.
66. Morgan CM, Schatz H. Recurrent multifocal choroiditis. Ophthalmology. 1986;93:1138-1147.
67. Singerman LJ. Letter. Ophthalmology. 1986;93:1143-1147.
68. Dreyer RF, Gass DJ. Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch Ophthalmol. 1984;102:1776-1784.
69. Flaxel CJ, Owens SL, Mulholland B, et al. The use of corticosteroids for choroidal neovascularisation in young patients. Eye. 1998;12:266-272.
70. Olsen TW, Capone A Jr, Sternberg P Jr, et al. Subfoveal choroidal neovascularization in punctate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology. 1996;103:2061-2069.
71. Eckstein M, Wells JA, Aylward B, et al. Surgical removal of non-age-related subfoveal choroidal neovascular membranes. Eye. 1998;12:775-780.
72. Chatterjee S, Gibson JM. Photodynamic therapy: a treatment option in choroidal neovascularization secondary to punctate inner choroidopathy. Br J Ophthalmol. 2003;87:925-927.
73. Hoogstede HA, Copper AC. A case of macular subretinal neovascularisation in chronic uveitis probably caused by sarcoidosis. Br J Ophthalmol. 1982;66:530-535.
74. Gragoudas ES, Regan CD. Peripapillary subretinal neovascularization in presumed sarcoidosis. Arch Ophthalmol. 1981;99:1194-1197.
75. Abe K, Shiraki K, Yasunari T, et al. Peripapillary subretinal neovascularization in sarcoidosis: remission and exacerbation during oral corticosteroid therapy. Jpn J Ophthalmol. 2002;46:95-99.
76. Moorthy RS, Chong LP, Smith RE, et al. Subretinal neovascular membranes in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1993;116:164-170.
77. Farah ME, Costa RA, Muccioli C, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2002;134:137-139.
78. Greve MDJ, Hilson TR, Hinz BJ, et al. Surgical removal of subfoveal choroidal neovascular membranes in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1999;237:1039-1045.
79. Navajas EV, Costa RA, Farah ME, et al. Indocyanine green-mediated photothrombosis combined with intravitreal triamcinolone for the treatment of choroidal neovascularization in serpiginous choroiditis. Eye. 2003;17:563-566.
80. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporine-induced resolution of choroidal neovascularization associated with sympathetic ophthalmia. Arch Ophthalmol. 1998;116:249-250.